News

The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. ALCL is a rare form of non-Hodgkin lymphoma

The approval enables to use of ligelizumab to treat CSU, also called chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. CSU is

Under the deal, the US-based biotech company has granted an exclusive, worldwide, royalty-bearing license to Takeda Pharmaceutical pertaining to cell and non-cell therapy products that modulate targets identified

This regulatory submission was based on Phase III FIDELIO-DKD trial data, which were recently presented at the American Society of Nephrology’s (ASN) Kidney Week Reimagined 2020, and simultaneously

“The acquisition of Kashiv Specialty aligns strongly with our Amneal 2.0 growth strategy which we expect will deliver substantial value for our Specialty and Generics businesses,” said Chirag

VIR-7832, a neutralising Covid-19 antibody, attaches to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1. According to GSK, the preclinical data suggests that VIR-7832 has two distinguishing

According to the India-based pharma company, the Sputnik V vaccine has been recommended by an independent data and safety monitoring board (DSMB) to advance to a phase 3

This new 103,720 ft2 facility will support clinical development of Rocket’s growing pipeline of lentivirus (LV) and adeno-associated virus (AAV) gene therapies from discovery through pivotal trials, with

The Companies have agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals.